IJCM  Vol.9 No.6 , June 2018
Chryseobacterium indologenes Bacteremia: Clinical and Microbiological Characteristics of an Emerging Infection
Purpose: Since Chryseobacterium indologenes (C. indologenes) is a rare human pathogen, its clinical significance has not yet been fully established. C. indologenes contamination of medical devices involving fluids and of surgical implants has led to an increasing number of serious infectious reported in recent years, mainly in patients in extremes ages and an immunocompromised state. In this study, we describe the clinical and microbiological characteristics of seven adult patients with C. indologenes bacteremia treated in a tertiary medical center in Israel over a six-year period. Methods: Adult patients hospitalized in Rabin Medical Center, Israel, with a blood culture positive for C. indologenes during the period 2009-2014 were identified retrospectively and their medical records were reviewed. Results: Seven episodes of C. indologenes bacteremia in seven patients were identified during the study period. Five patients were females; the mean age was 76.8 years (41 - 92). Serious underlying conditions were present in all patients. All patients but one, presented after a recent invasive healthcare related intervention. Two patients required mechanical ventilation. Two patients died. All but one isolates were susceptible to ciprofloxacin. Conclusions: Despite our limited number of cases, to the best of our knowledge, our study serves as the largest cohort of adult patients with C. indologenes bacteremia reported in recent years.
Cite this paper
Alon, D. , Karniel, E. , Zohar, I. and Stein, G. (2018) Chryseobacterium indologenes Bacteremia: Clinical and Microbiological Characteristics of an Emerging Infection. International Journal of Clinical Medicine, 9, 520-527. doi: 10.4236/ijcm.2018.96045.
[1]   Yabuuchi, E., Hashimoto, Y., Ezaki, T., Ido, Y. and Takeuchi, N. (1990) Genotypic and Phenotypic Differentiation of Flavobacterium indologenes Yabuuchi et al. 1983 from Flavobacterium gleum Holmes et al. 1984. Microbiology and Immunology, 34, 73-76.

[2]   Hsueh, P.R., Hsiue, T.R., Wu, J.J., Teng, L.J., Ho, S.W., Hsieh, W.C., et al. (1996) Flavobacterium indologenes Bacteremia: Clinical and Microbiological Characteristics. Clinical Infectious Diseases, 23, 550-555.

[3]   Kirby, J.T., Sader, H.S., Walsh, T.R. and Jones, R.N. (2004) Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of Chryseobacteriums pp: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001). Journal of Clinical Microbiology, 42, 445-448.

[4]   Shahul, H.A., Manu, M.K., Mohapatra, A.K. and Chawla, K. (2014) Chryseobacterium indologenes Pneumonia in a Patient with Non-Hodgkin’s Lymphoma. BMJ Case Reports, 2014.

[5]   Corbella, M., Brandolini, M., Cambieri, P., Decembrino, N., Pagani, M., Bottazzi, A., et al. (2017) A Catheter-Related Bloodstream Infection Caused by Chryseobacterium indologenes Successfully Treated with Antibiotic-Lock Rescue Therapy. New Microbiologica, 40, 223-225.

[6]   Afshar, M., Nobakht, E. and Lew, S.Q. (2013) Chryseobacterium indologenes Peritonitis in Peritoneal Dialysis. BMJ Case Reports, 2013.

[7]   Lu, P.C. and Chan, J.C. (1997) Flavobacterium indologenes Keratitis. Ophthalmologica, 211, 98-100.

[8]   Lin, Y.T., Jeng, Y.Y., Lin, M.L., Yu, K.W., Wang, F.D. and Liu, C.Y. (2010) Clinical and Microbiological Characteristics of Chryseobacterium indologenes Bacteremia. Journal of Microbiology, Immunology and Infection, 43, 498-505.

[9]   Al-Tatari, H., Asmar, B.I. and Ang, J.Y. (2007) Lumboperitonial Shunt Infection Due to Chryseobacterium indologenes. The Pediatric Infectious Disease Journal, 26, 657-659. https://doi.org/10.1097/INF.0b013e3180616d25

[10]   Kienzle, N., Muller, M. and Pegg, S. (2001) Chryseobacterium in Burn Wounds. Burns, 27, 179-182.

[11]   Hsueh, P.R., Wu, J.J., Hsiue, T.R. and Hsieh, W.C. (1995) Bacteremic Necrotizing Fasciitis Due to Flavobacterium odoratum. Clinical Infectious Diseases, 21, 1337-1338.

[12]   Aykac, K., Ozsurekci, Y., Tuncer, O., Sancak, B., Cengiz, A.B., Kara, A., et al. (2016) Six Cases during 2012-2015 and Literature Review of Chryseobacterium indologenes Infections in Pediatric Patients. Canadian Journal of Microbiology, 62, 812-819.

[13]   Mukerji, R., Kakarala, R., Smith, S.J. and Kusz, H.G. (2016) Chryseobacterium indologenes: An Emerging Infection in the USA. BMJ Case Reports, 2016.

[14]   Soydan, S., Ignak, S., UnayDemirel, O., Karadag, G., Aykent, A. and Aslan, S. (2017) Chryseobacterium indologenes Infection in a Patient with Chronic Obstructive Pulmonary Disease. Drug Discoveries & Therapeutics, 11, 165-167.

[15]   Nulens, E., Bussels, B., Bols, A., Gordts, B. and Van Landuyt, H.W. (2001) Recurrent Bacteremia by Chryseobacterium indologenes in an Oncology Patient with a Totally Implanted Intravascular Device. Clinical Microbiology and Infection, 7, 391-393.

[16]   Calderón, G., García, E., Rojas, P., García, E., Rosso, M. and Losada, A. (2011) Chryseobacterium indologenes Infection in a Newborn: A Case Report. Journal of Medical Case Reports, 5, 10.

[17]   Bayraktar, M.R., Aktas, E., Ersoy, Y., Cicek, A. and Durmaz, R. (2007) Postoperative Chryseobacterium indologenes Bloodstream Infection Caused by Contamination of Distillate Water. Infection Control & Hospital Epidemiology, 28, 368-369.

[18]   Hsueh, P.R., Teng, L.J., Yang, P.C., Ho, S.W., Hsieh, W.C. and Luh, K.T. (1997) Increasing Incidence of Nosocomial Chryseobacterium indologenes Infections in Taiwan. European Journal of Clinical Microbiology & Infectious Diseases, 16, 568-574.

[19]   Chang, Y.C., Lo, H.H., Hsieh, H.Y. and Chang, S.M. (2015) Identification, Epidemiological Relatedness, and Biofilm Formation of Clinical Chryseobacterium indologenes Isolates from Central Taiwan. Journal of Microbiology, Immunology and Infection, 48, 559-564.

[20]   Fraser, S.L. and Jorgensen, J.H. (1997) Reappraisal of the Antimicrobial Susceptibilities of Chryseobacterium and Flavobacterium Species and Methods for Reliable Susceptibility Testing. Antimicrobial Agents and Chemotherapy, 41, 2738-2741.